Skip to content
Open access

Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent invasive pneumococcal disease in Canada: A Canadian Immunization Research Network (CIRN) study

Oct 2026 · Epidemiology and Infection · Vol 154 · 0 citations · 22 references

Abstract

Abstract The effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) to prevent vaccine-serotype (VT) invasive pneumococcal disease (IPD) in children aged 2–59 months was assessed using data from 4 geographically defined areas in Canada with IPD surveillance, including immunization status. VT IPD cases and IPD controls with non-PCV13 types or PCV13-related serotypes (NVT/NR) during the years 2010–2019 were eligible. Vaccine effectiveness (VE) was estimated by the indirect cohort method, using multivariate logistic regression models. In total, 367 VT IPD cases and 564 NVT/NR IPD controls were included. VE of ≥1 dose of PCV13 against VT IPD was 70% [95% confidence interval: 49%–83%], lower against serotype 19A IPD (VE = 58%; 95%CI, 14%–80%) and against serotype 3 IPD (VE = 46%; 95%CI, −36% to 79%), but higher against all other PCV13 serotypes (VE = 90%; 95%CI, 78%–96%). Waning of protection was seen against all VT IPD, particularly for serotype 3, with a VE of 89% [54%–97%] during the first 5 months after the third dose but no protection remaining after 18 months. As serotype 3 and serotype 19A are still frequent causes of IPD in children, more effective vaccines are needed.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.